摘要
目的:评价丙戊酸镁辅助治疗精神分裂症的疗效与安全性。方法:应用循证医学方法对符合标准的11项研究进行分析,评价丙戊酸镁辅助治疗精神分裂症的有效率、症状学变化的差异。结果:丙戊酸镁在联合抗精神病药物的基础上,症状改善显著(PANSS:WMD:-4.33,95%CI:-4.86～-3.81,Z=16.24,P<0.001;BPRS:WMD:-7.03,95%CI:-8.45～-5.61,Z=9.70,P<0.001),并且明显提高有效率(OR=2.06,95%CI:1.44～2.95,Z=3.93,P<0.001),但是痊愈率差异不甚显著(OR=1.34,95%CI:0.63～2.83,Z=0.76,P=0.45)。结论:丙戊酸镁在抗精神病药物的基础上,对精神分裂症可以明显改善症状,提高有效率。
Objective： To assess the difference between magnesium valproate and carbonate lithium in treatment of mania. Methods： 11 studies meeting our criteria were analyzed by based-evidence medicine, comparing the difference in symptoms changes and efficacy. Results： The significant differences in change symptoms by magnesium valproate and antipsychotics comparing to only psychotics （ PANSS ： WMD ： - 4. 33,95 % CI ： - 4. 86 - - 3.81, Z = 16. 24, P 〈 0. 001 ; BPRS ： WMD ： - 7. 03,95 % CI ： - 8.45 - - 5.61, Z = 9.70, P 〈 0. 001 ） , and higher effective rate also was found （ OR = 2. 06,95 % CI ： 1.44- 2. 95, Z = 3.93, P 〈 0. 001 ）. But no difference in full remission rate was found between magnesium valproate adding on atipsychotics and only antipsychotics（ OR = 1.34,95% C1：0. 63 ~ 2.83, Z = 0. 76 ,P = O. 45 ）. Conclusion： The effect Of maguesium valproate adding on antipsychotics had significant changes of symptoms and higher effective rate in treatment of schizoprenia.
出处
《中国药物评价》
2012年第3期225-229,共5页
Chinese Journal of Drug Evaluation
